•  

Posts Tagged: acquisitions

Zealand Pharma Acquires Encycle Therapeutics

Our portfolio company, Encycle Therapeutics, has been acquired by Danish Zealand Pharma. The transaction strengthens the leadership of Zealand Pharma (NASDAQ: ZEAL) in peptide therapeutics and in targeting gastrointestinal diseases with the addition of a pre-clinical, orally-delivered macrocycle peptide (integrin alpha-4-beta-7 inhibitor). Encycle is founded on research coming from University of Toronto - a TIAP member institution. Read more here: http://bit.ly/2W2hH4N   Read more

MaRS Innovation’s top 10 portfolio stories for 2014

MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses. Here are our picks for the top 10 news stories from MaRS Innovation's portfolio. 1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study ... Read more

ClevrU Corp. acquires NewMindsets Inc. to transform online education market

Deal strengthens competitiveness of online learning platform for global mobile learners WATERLOO, ON, Canada (April 23, 2013) — ClevrU Corporation today announced that it has acquired NewMindsets Inc., a company founded on online pedagogy researched and developed by two Schulich School of Business professors that has provided leading-edge educational content and services to over 10,000 Schulich students at York University over the past decade. Through the acquisition, ClevrU will fully integrate NewMindsets’ proven e-teaching pedagogy in leadership, researched and developed by Professors ... Read more